Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Pulmonary Arterial Hypertension Market

Pulmonary Arterial Hypertension Market Share

  • Report ID: GMI1939
  • Published Date: Aug 2021
  • Report Format: PDF

Pulmonary Arterial Hypertension Market Share

Some of the major companies operating in the market are:

  • Bayer AG
  • Eli Lilly and Company
  • Gilead Sciences, Inc
  • GlaxoSmithKline plc
  • Johnson & Johnson 

These major participants are adopting strategic formulations such as new product development & commercialization, commercial expansion, distribution agreements for business expansion. Moreover, these leaders are investing heavily in developing products, thereby fuelling the revenue generation.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Pulmonary arterial hypertension market size had surpassed USD 6.6 billion in 2020 and will witness a CAGR of 6% through 2027.

Endothelin receptor antagonist segment will observe a CAGR of 5.5% through 2027 as the drug is highly recommended to reverse the damage of heart & lungs and slow the progression of PAH.

Oral segment had captured a revenue share of over 69% in 2020 owing to higher preference for this route of administration due to the convenience and non-invasiveness.

U.S. dominated North America pulmonary arterial hypertension market and will record a valuation of over USD 6.25 billion by 2027 owing to increasing hospital admissions for PAH and growing supportive government initiatives.

Germany held 10% of the market share in 2020 and will record over USD 194 million by 2027 owing to rising prevalence of PAH in the country.

Pulmonary Arterial Hypertension Market Scope

Buy Now


Premium Report Details

  • Base Year: 2020
  • Companies covered: 7
  • Tables & Figures: 143
  • Countries covered: 18
  • Pages: 120
 Download Free Sample